SJS Investment Consulting
ADCT icon

SJS Investment Consulting’s ADC Therapeutics ADCT Stock Holding History

SJS Investment Consulting’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.07K Buy
877
+845
+2,641% +$988 ﹤0.01% 2474
2026
Q2 		$35 Buy
+32
New +$93 ﹤0.01% 2785

Other funds holding ADCT

Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Blue Owl Capital Holdings
Blue Owl Capital Holdings New York $548M AUM 35.34% 1-Year Est. Return

SJS Investment Consulting's ADCT Position: Q3 2026 in Review

SJS Investment Consulting increased its ADC Therapeutics (ADCT) stake by 2,641% in Q3 2026, buying an estimated $988 and bringing the position to 877 shares worth $1.07K. The position accounts for ﹤0.01% of the portfolio, ranked #2474.

SJS Investment Consulting first reported a position in ADCT in Q2 2026 and has held it in 2 quarters since. 75 funds tracked by Wall St. Rank hold ADCT as of Q3 2026.

  • SJS Investment Consulting held 877 shares of ADC Therapeutics worth $1.07K as of Q3 2026.
  • SJS Investment Consulting bought 845 ADC Therapeutics shares in Q3 2026, an estimated $988.
  • ADC Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q3 2026, its #2474 holding.
  • SJS Investment Consulting first reported a position in ADC Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 75 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.